Literature DB >> 9279142

Recombinant human DNase (rhDNase) in cystic fibrosis: is it cost effective?

S P Conway1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9279142      PMCID： PMC1717232          DOI： 10.1136/adc.77.1.1

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  10 in total

1.  A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis.

Authors:  R C Hubbard; N G McElvaney; P Birrer; S Shak; W W Robinson; C Jolley; M Wu; M S Chernick; R G Crystal
Journal:  N Engl J Med       Date:  1992-03-19       Impact factor: 91.245

2.  A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis.

Authors:  J Menzin; G Oster; L Davies; M F Drummond; W Greiner; C Lucioni; J L Merot; F Rossi; J G vd Schulenburg; E Souêtre
Journal:  Int J Technol Assess Health Care       Date:  1996       Impact factor: 2.188

3.  rhDNase in cystic fibrosis.

Authors:  S P Range; A J Knox
Journal:  Thorax       Date:  1995-04       Impact factor: 9.139

4.  Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients.

Authors:  H G Heijerman; R N van Rossem; W Bakker
Journal:  Neth J Med       Date:  1995-06       Impact factor: 1.422

5.  Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study.

Authors:  M L Aitken; W Burke; G McDonald; S Shak; A B Montgomery; A Smith
Journal:  JAMA       Date:  1992-04-08       Impact factor: 56.272

6.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors:  H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

7.  Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.

Authors:  B W Ramsey; S J Astley; M L Aitken; W Burke; A A Colin; H L Dorkin; J D Eisenberg; R L Gibson; I R Harwood; D V Schidlow
Journal:  Am Rev Respir Dis       Date:  1993-07

8.  Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis.

Authors:  G Oster; D M Huse; M J Lacey; M M Regan; H J Fuchs
Journal:  Ann Pharmacother       Date:  1995-05       Impact factor: 3.154

Review 9.  Clinical studies of rhDNase in moderately and severely affected patients with cystic fibrosis--an overview.

Authors:  M E Hodson
Journal:  Respiration       Date:  1995       Impact factor: 3.580

10.  Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis.

Authors:  P L Shah; S F Scott; D M Geddes; M E Hodson
Journal:  Respir Med       Date:  1995-08       Impact factor: 3.415
  10 in total
  1 in total

Review 1.  Recent advances in cystic fibrosis.

Authors:  I J Doull
Journal:  Arch Dis Child       Date:  2001-07       Impact factor: 3.791
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.